Systems Biology in Drug Discovery: Using Predictive Biomedicine to Guide Development Choices for Novel Agents in Cancer

Systems Biomedicine: Concepts and Perspectives

Volumn , Issue , 2009, Pages 399-414

  Tucker Kellogg, Greg ^a,b   Aggarwal, Amit ^a   Blanchard, Kerry ^b   Gaynor, Richard ^c  

^a Eli Lilly Singapore Pte Ltd   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957846576     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-372550-9.00017-1     Document Type: Chapter

References (62)

1. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Beerenwinkel N., Antal T., Dingli D., et al. Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 2007, 3:e225.
3. Berns K., Hijmans E.M., Mullenders J., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004, 428:431-437.
4. Bild A.H., Yao G., Chang J.T., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439:353-357.
5. Butcher E.C., Berg E.L., Kunkel E.J. Systems biology in drug discovery. Nat. Biotech. 2004, 22:1253-1259.
6. Carpten J.D., Faber A.L., Horn C., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
7. Chang H.Y., Sneddon J.B., Alizadeh A.A., et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS. Biol. 2004, 2:E7.
8. Chi J.T., Chang H.Y., Wang N.N., Chang D.S., Dunphy N., Brown P.O. Genomewide view of gene silencing by small interfering RNAs. Proc. Natl. Acad. Sci. USA 2003, 100:6343-6346.
9. Czauderna F., Fechtner M., Aygün H., et al. Functional studies of the PI-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic. Acids. Res. 2003, 31:670-682.
10. de Tayrac M., Etcheverry A., Aubry M., et al. Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer 2009, 48:55-68.
11. Di Cosimo S., Baselga J. Targeted therapies in breast cancer: where are we now?. Eur. J. Cancer 2008, 44:2781-2790.
12. Dowsett M., Dunbier A.K. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res. 2008, 14:8019-8026.
13. Dressman H.K., Berchuck A., Chan G., et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 2007, 25:517-525.
14. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
15. Fiebig H.H., Maier A., Burger A.M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 2004, 40:802-820.
16. Fiebig H.H., Schuler J., Bausch N., Hofmann M., Metz T., Korrat A. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics 2007, 4:197-209.
17. Fitzgerald J.B., Schoeberl B., Nielsen U.B., Sørger P.K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2006, 2:458-466.
18. Garber K. From human to mouse and back: "tumorgraft" models surge in popularity. J. Natl. Cancer Inst. 2009, 101:6-8.
19. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
20. Greenman C., Stephens P., Smith R., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
21. Gund P., Maliski E., Brown F. Embracing complexity in drug discovery. Curr. Opin. Drug Discov. Devel. 2007, 10:252-253.
22. Hall P.S., Cameron D.A. Current perspective-trastuzumab. Eur. J. Cancer 2009, 45:12-18.
23. Hsieh A.C., Bo R., Manola J., et al. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic. Acids Res. 2004, 32:893-901.
24. Huang E., West M., Nevins J.R. Gene expression profiling for prediction of clinical characteristics of breast cancer. Recent Prog. Horm. Res. 2003, 58:55-73.
25. Ivshina A.V., George J., Senko O., et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66:10292-10301.
26. Jordan V.C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug. Discov. 2003, 2:205-213.
27. Kim M.S., Jeong E.G., Yoo N.J., Lee S.H. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br. J. Cancer 2008, 98:1533-1535.
28. Kumar N., Hendriks B.S., Janes K.A., de Graaf D., Lauffenburger D.A. Applying computational modeling to drug discovery and development. Drug. Discov. Today 2006, 11:806-811.
29. Lenz G., Davis R.E., Ngo V.N., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
30. Li A., Walling J., Kotliarov Y., et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol. Cancer Res. 2008, 6:21-30.
31. Manning M., Aggarwal A., Gao K., Tucker-Kellogg G. Scaling the walls of discovery: using semantic metadata for integrative problem solving. Brief. Bioinform. 2009, 10:164-176.
32. McLendon R., Friedman A., Bigner D. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008.
33. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 2006, 33:369-385.
34. Miller L.D., Liu E.T. Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res. 2007, 9:206.
35. Miller L.D., Smeds J., George J., et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102:13550-13555.
36. Mirzoeva O.K., Das D., Heiser L.M., et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009, 69:565-572.
37. Neve R.M., Chin K., Fridlyand J., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
38. Ngo V.N., Davis R.E., Lamy L., et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006, 441:106-110.
39. Nupponen N., Hyytinen E.R., Kallioniemi A.H., Visakorpi T. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet. Cytogenet. 1998, 101:53-57.
40. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
41. Perou C.M., Sørlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
42. Petrelli A., Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 2008, 15:422-432.
43. Potti A., Nevins J.R. Utilization of genomic signatures to direct use of primary chemotherapy. Curr. Opin. Genet. Devel. 2008, 18:62-67.
44. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 2006, 12:1294-1300.
45. Ross D.T., Scherf U., Eisen M.B., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 2000, 24:227-235.
46. Salter K.H., Acharya C.R., Walters K.S., et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE 2008, 3:e1908.
47. Sausville E.A., Burger A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006, 66:3351-3354.
48. Shaffer A.L., Emre N.C., Lamy L., et al. IRF4 addiction in multiple myeloma. Nature 2008, 454:226-231.
49. Sharma A., Jusko W.J. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br. J. Clin. Pharmacol. 1998, 45:229-239.
50. Smith V., Wirth G.J., Fiebig H.H., Burger A.M. Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genomics Proteomics 2008, 5:263-273.
51. Sørlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
52. Staunton J.E., Slonim D.K., Coller H.A., et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 2001, 98:10787-10792.
53. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68:6084-6091.
54. Ventura A.C., Jackson T.L., Merajver S.D. On the role of cell signaling models in cancer research. Cancer Res. 2009, 69:400-402.
55. Vieth M., Higgs R.E., Robertson D.H., Shapiro M., Gragg E.A., Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 2004, 1697:243-257.
56. Vieth M., Sutherland J.J., Robertson D.H., Campbell R.M. Kinomics: characterizing the therapeutically validated kinase space. Drug. Discov. Today 2005, 10:839-846.
57. West M., Blanchette C., Dressman H., et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. USA 2001, 98:11462-11467.
58. West M., Ginsburg G.S., Huang A.T., Nevins J.R. Embracing the complexity of genomic data for personalized medicine. Genome. Res. 2006, 16:559-566.
59. Whitehurst A.W., Bodemann B.O., Cardenas J., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446:815-819.
60. Zhang L., Sinha V., Forgue S.T., et al. Model-based drug development: the road to quantitative pharmacology. J. Pharmacokinet. Pharmacodyn. 2006, 33:369-393.
61. Zhang L., Pfister M., Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 2008, 10:552-559.
62. Zhu J., Zhang B., Schadt E.E. A systems biology approach to drug discovery. Adv. Genet. 2008, 60:603-635.